COMy 2022 | The impact of gain/amp(1q) in patients with myeloma
In this video, Mattia D’Agostino, MD, University of Turin, Turin, Italy, briefly discusses the impact of gain or amplification of chromosome 1q in myeloma, drawing focus on the poor risk associated with patients who have this genetic abnormality. Dr D’Agostino also discusses the role of this abnormality in relapsed/refractory (R/R) disease. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Transcript (edited for clarity)
Gain or amplification of 1q predicts poor-risk in newly diagnosed multiple myeloma patients, and now we observed this effect also in relapsed/refractory disease. The difference is that in the refractory disease, the percentage of patients that are positive are so much higher, and also the clone that carried the 1q aberrations is much higher. So, it could be also more important in the newly diagnosed multiple myeloma cases...
Gain or amplification of 1q predicts poor-risk in newly diagnosed multiple myeloma patients, and now we observed this effect also in relapsed/refractory disease. The difference is that in the refractory disease, the percentage of patients that are positive are so much higher, and also the clone that carried the 1q aberrations is much higher. So, it could be also more important in the newly diagnosed multiple myeloma cases. So also, in relapsed/refractory setting, 1q abnormalities are predicting a poor prognosis for our patients.
Read more...
